IOVAIovance Biotherapeutics, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

-$10M-804.5% margin

Operating Income

-$461M-38735.0% margin

Net Income

-$444M-37345.4% margin

EPS (Diluted)

$-1.89

Cash Flow

Operating Cash Flow

-$362M

Free Cash Flow

-$384M

Stock-Based Comp.

$63M

Balance Sheet

Total Assets

$780M

Total Liabilities

$196M

Stockholders' Equity

$585M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	-$10M	$0	—
Operating Income	-$461M	-$399M	-15.5%
Net Income	-$444M	-$396M	-12.2%

IOVA FY 2023 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena